Statin use is associated with improved survival in patients with advanced heart failure receiving resynchronization therapy

Congestive Heart Failure

Volumn 15, Issue 4, 2009, Pages 159-164

  Sumner, Andrew D ^a   Boehmer, John P ^b   Saxon, Leslie A ^c   Carson, Peter ^d   Feldman, Arthur M ^e   Galle, Elizabeth ^f   Bristow, Michael R ^g  

^a LEHIGH VALLEY HOSPITAL   (United States)

^b PENN STATE COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e THOMAS JEFFERSON UNIVERSITY   (United States)

^f Boston Scientific CRM   (United States)

^g UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CERIVASTATIN; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOOP DIURETIC AGENT; MEVINOLIN; PRAVASTATIN; SIMVASTATIN; SPIRONOLACTONE;

AGED; ARTICLE; CARDIAC RESYNCHRONIZATION THERAPY; CARDIOVERSION; CONTROLLED STUDY; DEFIBRILLATION; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DISEASE DURATION; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART MUSCLE CONDUCTION DISTURBANCE; HEART RATE; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK REDUCTION; SURVIVAL RATE; SYSTOLIC BLOOD PRESSURE;

AGED; CARDIAC PACING, ARTIFICIAL; CHRONIC DISEASE; COMBINED MODALITY THERAPY; DEFIBRILLATORS, IMPLANTABLE; FEMALE; HEART FAILURE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; PROPORTIONAL HAZARDS MODELS; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME; UNITED STATES;

EID: 67651184162     PISSN: 15275299     EISSN: 17517133     Source Type: Journal    
DOI: 10.1111/j.1751-7133.2009.00057.x     Document Type: Article

References (31)

1. AHA. Heart Disease and Stroke Statistics: 2004 Update. Dallas, TX: American Heart Association; 2003.
2. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293-302.
3. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA. 1995;273:1450-1456.
4. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med. 1996;334:1349-1355.
5. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353:2001-2007.
6. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999;341:709-717.
7. Bristow MR, Saxon LA, Boehmer J, et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med. 2004;350:2140-2150.
8. Kadish A, Dyer A, Daubert JP, et al. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med. 2004;350:2151-2158.
9. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. JAMA. 1998;279:1615-1622.
10. Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20536 high risk individuals: A randomized placebo control trial. Lancet. 2002;360:7-22.
11. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary artery disease: The Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
12. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339:1349-1357.
13. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335:1001-1009.
14. Kjekshus J, Pedersen T, Olsson A, et al. The effects of simvastatin on the incidence of heart failure with coronary heart disease. J Card Fail. 1997;3:249-254.
15. Rauchhaus M, Coats AJS, Anker SD. The endotoxin-lipoprotein hypothesis. Lancet. 2000;356:930-933.
16. Sukhova GK, Williams JK, Libby P. Statins reduce inflammation in atheroma of nonhuman primates independent of effects on serum cholesterol. Arterioscler Thromb Vasc Biol. 2002;22:1452-1458.
17. Laufs U. Beyond lipid-lowering: Effects of statins on endothelial nitric oxide. Eur J Clin Pharmacol. 2003;58:719-731.
18. Anker SD, von Haehling S. Inflammatory mediators in chronic heart failure: An overview. Heart. 2004;90:464-470.
19. Rauchhaus M, Clark AL, Doehner W, et al. The relationship between cholesterol and survival in patients with chronic heart failure. J Am Coll Cardiol. 2003;42:1933-1940.
20. Horwich TB, MacLellan WR, Fonarow GC. Statin therapy is associated with improved survival in ischemic and non-ischemic heart failure. J Am Coll Cardiol. 2004;43:642-648.
21. Mozaffarian D, Nye R, Levy WC. Statin therapy is associated with lower mortality among patients with severe heart failure. Am J Cardiol. 2004;93:1124-1129.
22. Kjekshus J, Apetrei E, Barrios V, et.al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med. 2007;357:2248-2261.
23. GISSI HF Investigators. Effects of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): A randomized, double blind, placebo controlled trial. Lancet. 2008;372:1231-1239.
24. Bristow MR, Feldman AM, Saxon LA. Heart failure management using implantable devices for intraventricular resynchronization: Comparison of Medical Therapy, Pacing, and Defibrillation in Chronic Heart Failure (COMPANION) trial. J Card Fail. 2000;6:276-285.
25. Segal R, Pitt B, Wilson PP, et al. Effects of HMG-COA reductase inhibitors (statins) in patients with heart failure. Eur J Heart Fail. 2000;2(S1):96.
26. Vyas AK, Hongsgeng G, Moss AJ, et al. Reduction in ventricular tachyarrhythmias with statins in the multicenter automatic defibrillator implantation trial (MADIT)-II. J Am Coll Cardiol. 2006;47:769-773.
27. Goldberger JL, Subacius H, Schaechter A, et al. Effects of statin therapy on arrhythmic events and survival in patients with nonischemic dilated cardiomyopathy. J Am Coll Cardiol. 2006;48:1228-1233.
28. Dickinson MG, Ip JH, Olshansky B, et al. Statin use was associated with reduced mortality in both ischemic and nonischemic cardiomyopathy and in patients with implantable defibrillators: Mortality data and mechanistic insights from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). Am Heart J. 2007;153:573-578.
29. Khush KK, Waters DD, Bittner V, et al. Effect of high-dose atorvastatin on hospitalizations for heart failure: Subgroup analysis of the Treating to New Targets (TNT) study. Circulation. 2007;115:576-583.
30. Cleland JGF, Daubert JC, Erdmann E, et.al. Longer-term effects of cardia resynchronization therapy on mortality in heart failure [the Cardiac Resynchronization-Heart Failure (CARE-HF) trial extension phase]. Eur Heart J. 2006;27:1928-1932.
31. Carson P, Anand I, O'Connor C, et al. Mode of death in advanced heart failure: The Comparison of Medical, Pacing, and Defibrillation Therapies in Heart Failure (COMPANION) trial. J Am Coll Cardiol. 2005;46:2329-2334.